The aim of this publication is to provide a snapshot of:
Select response data from the recent CARE™ Needs assessment on the current state of care and access to innovative medicines in Canada
Data is augmented with additional context and insights by the CARE™ Rheumatology Faculty
The need for greater and more efficient access to approved innovative options in PsA is evident and is necessary to drive further improvement in patient outcomes.
Efforts moving forward will focus on highlighting inconsistencies and deficiencies in current processes for approval and funding of novel agents (and the potential downstream effect this has on the overall Canadian landscape) and explore the continued (and lasting) impact that the COVID-19 pandemic will have on rheumatology care.
The CARE™ Rheumatology Faculty plan to share their perspectives, informed by the insights gathered from this assessment during the upcoming multidisciplinary virtual CARE™ National Congress on Accessing Innovation in Canada slated for June 25, 2021. They will also be reporting on news and data from the EULAR 2021 Congress. Stay Tuned!